Table 6.
Selected trials of combined chemotherapy for SCC of the esophagus
| Author | Regimen | Pathology | N (SCC) | Line | Response rate (%) |
|---|---|---|---|---|---|
| Iizuka55 | Cisplatin + vindesine | SCC | 31 | 1st | 16 |
| Iizuka56 | Cisplatin + 5-FU | SCC | 39 | 1st | 36 |
| Hayashi57 | Cisplatin (5 days) + 5-FU | SCC | 36 | 1st | 33 |
| Bleiberg58 | Cisplatin + 5-FU | SCC | 44 | 1st | 35 |
| Ilson59 | Cisplatin + 5-FU + paclitaxel | SCC/adeno | 61 (31) | 1st | 48 (SCC: 50) |
| Ilson60 | Cisplatin + irinotecan | SCC/adeno | 35 (12) | 1st | 57 (SCC: 66) |
| Conroy61 | Cisplatin + vinorelbine | SCC | 71 | 1st | 33 |
| Millar62 | Cisplatin + gemcitabine | SCC/adeno | 42 (14) | 1st | 45 (SCC: 71) |
| Laack63 | Cisplatin + docetaxel | SCC/adeno | 16 (10) | 1st | 31 (SCC: 40) |
| Lee64 | Cisplatin + capecitabine | SCC | 45 | 1st | 57 |
| Muro65 | Nedaplatin + 5-FU | SCC | 38 | 1st | 40 |
| Airoldi66 | Docetaxel + vinorelbine | SCC | 20 | 1st / 2nd | 60 (CR: 15) |
Abbreviations: SCC = squamous-cell carcinoma; adeno = adenocarcinoma; CR = complete response